Eosinophils from Hematopoietic Stem Cell Recipients Suppress Allogeneic T Cell Proliferation  by Andersson, Jennie et al.
Biol Blood Marrow Transplant 20 (2014) 1891e1898Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgBiologyEosinophils from Hematopoietic Stem Cell Recipients Suppress
Allogeneic T Cell ProliferationJennie Andersson 1,*, Julia Cromvik 2, Madeleine Ingelsten 1, Christine Lingblom1,
Kerstin Andersson 1, Jan-Erik Johansson 2, Christine Wennerås 1
1Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2Department of Hematology and Coagulation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenArticle history:
Received 29 April 2014
Accepted 21 August 2014
Key Words:
Eosinophil
Graft-versus-host disease
Suppression
T cell inﬂammation
Galectin-10Financial disclosure: See Acknowle
* Correspondence and reprint re
ment of Infectious Diseases/Clinic
burg, Guldhedsgatan 10A, 6th Floo
E-mail address: jennie.andersso
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2014 American Sociea b s t r a c t
Eosinophilia has been associated with less severe graft-versus-host disease (GVHD), but the underlying
mechanism is unknown. We hypothesized that eosinophils diminish allogeneic T cell activation in patients
with chronic GVHD. The capacity of eosinophils derived from healthy subjects and hematopoietic stem cell
(HSC) transplant recipients, with or without chronic GVHD, to reduce allogeneic T cell proliferation was
evaluated using a mixed leukocyte reaction. Eosinophil-mediated inhibition of proliferation was observed for
the eosinophils of both healthy subjects and patients who underwent HSC transplantation. Eosinophils from
patients with and without chronic GVHD were equally suppressive. Healthy eosinophils required cell-to-cell
contact for their suppressive capacity, which was directed against CD4þ T cells and CD8þ T cells. Neither
eosinophilic cationic protein, eosinophil-derived neurotoxin, indoleamine 2,3-dioxygenase, or increased
numbers of regulatory T cells could account for the suppressive effect of healthy eosinophils. Real-time
quantitative PCR analysis revealed signiﬁcantly increased mRNA levels of the immunoregulatory protein
galectin-10 in the eosinophils of both chronic GVHD patients and patients without GVHD, as compared with
those from healthy subjects. The upregulation of galectin-10 expression in eosinophils from patients suggests
a stimulatory effect of HSC transplantation in itself on eosinophilic galectin-10 expression, regardless of
chronic GVHD status. To conclude, eosinophils from HSC transplant recipients and healthy subjects have a T
cell suppressive capacity.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host disease (GVHD) remains an important
obstacle to the more wide-spread use of allogeneic he-
matopoietic stem cell (HSC) transplantation as a means to
cure malignant and nonmalignant hematologic diseases. A
gross estimate indicates that 15% of patients who undergo
transplantation die of GVHD; mortality rates of up to 90% are
seen for thosewho do not respond to corticosteroids, the ﬁrst
line of treatment [1]. New cell-based therapies for the pre-
vention and/or treatment of GVHD are showing promising
results: the efﬁcacy of naturally occurring regulatory T cells
(Tregs) [2] and mesenchymal stromal cells [3] have been
investigated in this context.
Eosinophilia has been coupled with more favorable out-
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ty for Blood and Marrow Transplantation.transplantation [4-7]. For instance, eosinophilia is more
frequent among blood stem cell transplant recipients with
low-risk chronic GVHD than among high-risk chronic GVHD
patients [8]. On the other hand, eosinophilia has been pro-
posed as a biomarker/diagnostic criterion for chronic GVHD
[9]. Further, a recent study argues against a predictive value
of eosinophilia for long-term outcomes of chronic GVHD [10].
Although these controversies exist, the mechanisms under-
lying the co-occurrence of eosinophilia and GVHD have not
been addressed. Because it is becoming increasingly clear
that eosinophils can regulate the function of lymphocytes
[11], we hypothesized that eosinophils might also have this
capacity in the transplantation setting.
In the 1980s, it was shown that puriﬁed eosinophil
cationic protein (ECP) and eosinophil-derived neurotoxin
(EDN) could inhibit lymphocyte proliferation [12]. Ode-
muyiwa et al. [13] reported that eosinophils could selectively
inhibit type 1 T helper cells via their constitutive expression
of indoleamine 2,3-dioxygenase (IDO), an enzyme involved
in tryptophan catabolism. One of the chief protein constitu-
ents of eosinophils is galectin-10, formerly known as the
Table 1
Patient Characteristics
Characteristic No. of Patients
Gender
Female 8
Male 5
Diagnosis
Acute myeloid leukemia 7
Myeloid ﬁbrosis 3
Malignant lymphoma 1
Acute lymphoid leukemia 1
Chronic myeloid leukemia 1
Conditioning
Reduced intensity 8
Myeloablative 5
Donor
Unrelated 9
Related 4
Stem cell source
Blood stem cells 13
HLA match
10/10 11
9/10 2
Eosinophilia* 1 of 12y
* Peripheral blood eosinophil count > .4  109 cells/L.
y One missing value.
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the T cellesuppressive function of CD4þCD25þ Tregs [16].
In the present study, we tested the hypothesis that
eosinophilic granulocytes exert immunoregulatory functions
in GVHD by examining if eosinophils decrease the high-level
T cell activation that characterizes GVHD. A mixed leukocyte
reaction (MLR) was used to test the ability of human eosin-
ophils to diminish allogeneic T cell proliferation. Eosinophils
from both healthy individuals and HSC transplant recipients
with or without chronic GVHD were studied. In addition,
potential T cellesuppressive mechanisms employed by eo-
sinophils were explored.
MATERIALS AND METHODS
Study Subjects
Adult patients who had undergone HSC transplantation (at 27 to 69
years of age) donated peripheral blood when visiting the bone marrow
transplant outpatient clinic at the Department of Hematology and Coag-
ulation, Sahlgrenska University Hospital, Gothenburg, Sweden. Blood
donations were made 4 to 90 months after transplantation. Patients were
diagnosed as either having chronic GVHD (limited/mild, n ¼ 2; extensive/
mild, n ¼ 5) or not having GVHD (n ¼ 6), using the Seattle [17] and the
National Institutes of Health [18] grading criteria. Anemia and systemic
glucocorticoid treatment were exclusion criteria. Additional patient
characteristics are listed in Table 1. Peripheral blood collected from
healthy adults served as the control material (n ¼ 50 peripheral blood
eosinophil donors in total). All study participants gave written, informed
consent. The study was approved by the local ethics committee in
Gothenburg.
Preparation of Responder Cells, Trigger Cells, and Eosinophils
Heparinized blood was mixed with 2% dextran to sediment the
erythrocytes, and peripheral blood mononuclear cells (PBMC) were then
puriﬁed using Ficoll density gradient centrifugation. The PBMC from
healthy subjects were used as responder cells. Trigger cells consisted of
pooled PBMC from 11 to 12 healthy donors, stored at 150C in dime-
thylsulfoxide. After hypotonic lysis of erythrocytes, eosinophils from both
the healthy subjects (eosinophilhealthy) and HSC transplant recipients
(eosinophilHSCT) were isolated from the polymorphonuclear cell fraction
by negative immunomagnetic depletion. Using a mixture of magnetic
beads (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) coupled with
anti-CD16, anti-CD3, anti-CD14, or anti-CD19 antibodies, an eosinophil
fractionwith a purity of> 95%was obtained. The purity was determined by
Diff-Quick staining (Dade Behring AG, Düdingen, Switzerland) of cytospun
eosinophil fractions. Aliquots of eosinophils originating from both the
healthy donors and HSC transplant recipients were stored frozen inRNAlater (Ambion, Paisley, UK) for subsequent RNA preparation and
analysis by real-time quantitative PCR.
MLR/Eosinophil Cocultures
The MLR cultures were set up using 1  105 responder cells and g-
irradiated (25 Gy; Department of Transfusion Medicine, Sahlgrenska Uni-
versity Hospital) trigger cells at a ratio of 1:1. Eosinophils from healthy
subjects were added either on the same day as the MLR cultures were
prepared (day 0) or 2 days later (day 2), at a ratio of either 1:1 (1  105
eosinophils) or 1:5 (2  104 eosinophils) to responders. In control exper-
iments, neutrophils (ie, the entire granulocyte fraction; 1  105 neutro-
phils) from healthy subjects were used in place of the eosinophils.
Eosinophils from HSC transplant recipients were added on day 0 at a ratio
of 1:1 to responders. In selected experiments, isotype control antibodies
(Mouse IgG1, clone 107.3; Rat IgG2a, clone RTK2758) and monoclonal
antibodies speciﬁc for ECP and EDN (clone EG2 and clone 616, respec-
tively), galectin-10 and IL-10 (clone B-F42 and clone B-S10, respectively),
and CD210 (clone 3F9) were added to the MLR/eosinophil cocultures (4 to
8 mg/mL). Additional control experiments using native EDN (.4 mg/well)
and native ECP (.4 mg/well) (both from Diagnostics Development AB) were
performed. MLR and MLR/eosinophilhealthy cocultures were also prepared
in transwell-96 culture plates. In these experiments, eosinophils were
seeded in transwell inserts (1.5  105 cells), whereas the MLR was
established in the receiver plate (1.5  105 responder cells plus 1.5  105
trigger cells). Cultures with transwell inserts that were either permissive
(3 mm) or nonpermissive (.4 mm) for PBMC/eosinophil cell-to-cell contact
were run in parallel. All cultures were prepared in the culture medium
RPMI 1640 that was supplemented with 10% human AB serum, 2 mM L-
glutamine, 50 mg/mL gentamicin, and .05 mM b-mercaptoethanol. Cultures
were incubated for either 5 days (ﬂow cytometry, see below) or 6 days
(proliferation assay, see below) at 37C in a humidiﬁed atmosphere that
contained 5% CO2.
Proliferation Assay
To assay cellular proliferation, 3H-thymidine (1 to 1.5 mCi/well) was
added on the sixth day of culture. After 6 hours, the cells were harvested
onto glass ﬁber ﬁlters, on top of which a melt-on scintillator was applied.
Incorporated 3H-thymidine was then detected using a b-counter and
quantiﬁed as counts per minute.
IDO Activity
IDO activity was quantiﬁed indirectly by measuring the levels of
kynurenine in the supernatants of the MLR/eosinophilhealthy cocultures. The
amount of kynurenine present was measured by high performance liquid
chromatography, as previously described [19]. To conﬁrm that the IDO ac-
tivity was not restricted owing to a lack of its substrate, the levels of tryp-
tophanwere measured in all the samples. External calibrators of tryptophan
and kynurenine were used for quantitation.
Flow Cytometry
MLR cultures and MLR/eosinophilhealthy cocultures were harvested on
the ﬁfth day of culture. The cells were stained for 30 minutes at 4C with
CD4-APC-H7 (clone SK3), CD8-FITC or CD8-PerCP-Cy5.5 (clone RPA-T8),
CD25-APC or CD25-PE (clone 2A3), and CD127-Alexa Fluor 647 or CD127-
FITC (clone HIL-7R-M21). Before intracellular staining for Ki-67, the cells
were ﬁxed and permeabilized using a Foxp3 Fixation/Permeabilization kit
(eBioscience, San Diego, CA). Subsequent staining with Ki-67-eFluor 450
(clone 20Raj1) was performed in permeabilization buffer. Data were ac-
quired on a FACSCantoII and analyzed using the FlowJo software.
RNA Extraction and cDNA Synthesis
RNAwas extracted from eosinophils using the RNeasy Mini kit (Qiagen,
Valencia, CA), according to the manufacturer’s instructions. RNA quality
and concentration were evaluated in the Experion Automated Electro-
phoresis System (Bio-Rad Laboratories, Berkeley, CA). Synthesis of cDNA
from total RNAwas carried out using AMV reverse transcriptase, PCR-dNTP
mix, RNase inhibitor, and the random primer pd(N)6 (all from Roche
Applied Bioscience, Mannheim, Germany). The protocol for cDNA synthesis
was as follows: 5 minutes at 20C, 50 minutes at 42C, 5 minutes at 70C,
and a ﬁnal step at 4C.
Real-Time Quantitative PCR
TaqMan gene expression assays (Applied Biosystems, Foster City,
CA) were used to analyze eosinophilic expression of the genes for
galectin-10 (#Hs00171342_m1) and hypoxanthine phosphoribosyl-
transferase 1 (reference, #Hs99999909_m1) using the 7500 real-time
PCR system and 7500 System SDS software (Applied Biosystems). The
Figure 1. Inhibitory effect of eosinophils on allogeneic T cell proliferation in vitro. MLR/eosinophil cocultures were established with eosinophils from both healthy
subjects (A, B) and HSC transplant recipients with chronic GVHD (C, n ¼ 7) or no GVHD (D, n ¼ 6). Eosinophils were added either on day 2 (A) or on the same day as
the MLR cultures were prepared (day 0, B-D). Neutrophils from healthy subjects were added on day 2 of culture (A). The ratio of eosinophils (or neutrophils) to
peripheral blood mononuclear cells (PBMC) in the cocultures is indicated below the x-axis (A). (B-D) The ratio of eosinophils to PBMC in the cocultures was 1:1 (þ).
Proliferation was assessed by measuring 3H-thymidine incorporation into the cells. The results are expressed as counts per minute. Each data point represents the
median value of 2 to 7 replicate cultures derived from 1 individual. Horizontal bars represent the group medians (A). Statistical analyses were performed using the
paired Wilcoxon signed-rank test (A-D) or the Mann-Whitney U-test (A).
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minutes at 50C, 1 cycle of 10 minutes at 95C, 40 cycles of 15 seconds
at 95C, and 1 minute at 60C. The Pfafﬂ method was used to
calculate the transcript levels of galectin-10 relative to those of hypo-
xanthine phosphoribosyltransferase 1, employing the algorithms:
(Etarget)DCt target (control-patient)/(Ereference)DCt reference (control-patient) [20]. Eosino-
phils from healthy subjects were used as controls.Statistics
The paired Wilcoxon signed-rank test and the Mann-Whitney U-
test were used to test for statistical signiﬁcance between groups. A P
value < .05 was considered to be statistically signiﬁcant. Statistical
analyses were performed using the GraphPad Prism version 5.0
software.RESULTS
Eosinophilic Inhibition of T Cell Proliferation is Cell
Numberedependent and Cell Typeespeciﬁc
Initially, we investigated the capacity of eosinophils from
healthy subjects to reduce ongoing allogeneic T cell prolif-
eration, in a 2-day-oldMLR.When eosinophils were added at
a ratio of 1:1 to responder cells, allogeneic T cell proliferation
was inhibited by 43% (median), as compared with MLR
cultures without eosinophils (P ¼ .007; n ¼ 15 peripheral
blood eosinophil donors) (Figure 1A). The use of fewer
eosinophils in theMLR (1:5 to responder cells) did not lead to
inhibition of allogeneic T cell proliferation (Figure 1A). When
we replaced the eosinophils with neutrophils, to exclude the
possibility of cell overcrowding accounting for the observed
inhibitory effect of eosinophils on allogeneic T cell prolifer-
ation, therewas no inhibition of allogeneic Tcell proliferation
(Figure 1A).Eosinophils from HSC Transplant Recipients Inhibit
Allogeneic T Cell Proliferation
For practical reasons, it was not possible to add eosino-
phils from transplant recipients to 2-day-old MLRs. There-
fore, we veriﬁed that the eosinophils from healthy subjects
were still able to reduce allogeneic T cell proliferation when
added on the same day the MLR cultures were prepared
(P ¼ .0001; n ¼ 14 peripheral blood eosinophil donors)
(Figure 1B). Eosinophils from HSC transplant recipients, both
with chronic GVHD (Figure 1C) and without GVHD
(Figure 1D), were also found to reduce allogeneic T cell
proliferation when added to MLR cultures (n ¼ 7 peripheral
blood eosinophil donors, P ¼ .016 and n ¼ 6 peripheral blood
eosinophil donors, P ¼ .031, respectively). Although the me-
dian level of T cell inhibition conferred by the eosinophils
from patients was either lower (chronic GVHD, median: 51%;
25th to 75th percentile: 30% to 80%) or higher (no GVHD,
median: 77%; 25th to 75th percentile: 27% to 92%) than that
mediated by the eosinophils from healthy controls (median:
67%; 25th to 75th percentile: 31% to 85%), there were no
statistically signiﬁcant differences between HSC transplant
recipients and healthy controls (chronic GVHD, P ¼ .43; no
GVHD, P ¼ .59). Further, no signiﬁcant difference in eosino-
philic suppressive capacity could be demonstrated when
comparing transplant recipients with chronic GVHD to
transplant recipients without GVHD (P ¼ .37).
Eosinophils Reduce the Frequencies of Proliferating CD8þ
T Cells, CD4þ Conventional T Cells, as well as that of Treg
Ki-67 is a DNA-binding protein that is expressed at all
stages of the cell cycle, except during the resting G0 phase
Figure 2. Inhibitory effects of healthy eosinophils on the frequencies of proliferating CD8þ T cells, CD4þ conventional T cells, and Treg during allogeneic T cell
proliferation. MLR cultures with (þ) or without () eosinophils, at a ratio of 1:1 to PBMC, were harvested on day 5 and stained with ﬂuorochrome-labeled monoclonal
antibodies directed against CD4, CD8, CD25, CD127, and Ki-67. (A, B) Representative dot plots, showing the gating strategy employed for deﬁning: (A) lymphocytes
based on forward scatter (FSC-A) and side-scatter (SSC-A); and (B) CD4þ T cells and CD8þ T cells by subgating from lymphocytes. (C) After gating on the CD4þ T cells,
further subgating was performed to locate CD4þ conventional T cells (Tcon) and CD4þCD25þCD127low T cells (Treg). (D-F) Ki-67þ T cells were located by further
subgating from CD8þ T cells (D), Tcon (E), and Treg (F). (G-I) Shown are the percentages of: Ki-67þCD8þ T cells (G), Ki-67þ Tcon (H), and Ki-67þ Treg (I) present in the
MLR and MLR/eosinophilhealthy cocultures. Each data point represents 1 ﬂow cytometric measurement for 1 individual (G-I). Horizontal bars represent the group
medians. Statistical analyses were performed using the paired Wilcoxon signed-rank test. n ¼ 6 peripheral blood eosinophil donors.
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the frequencies of proliferating (Ki-67þ) CD8þ T cells, CD4þ
conventional T cells, and Treg (CD4þCD25þCD127low) in MLR
cultureswith or without healthy eosinophils. The presence of
eosinophils resulted in reduced frequencies of proliferating
CD8þ T cells (Figure 2G), CD4þ conventional T cells
(Figure 2H), and CD25þCD127low Treg (Figure 2I).
Cell-to-Cell Contact is Required for Eosinophilic
Inhibition of Allogeneic T Cell Proliferation
To determine whether cell-to-cell contact is required for
eosinophils to inhibit the proliferation of allogeneic T cells,
we established MLR/eosinophilhealthy cocultures in transwell
culture systems. We found that the eosinophils reduced
allogeneic T cell proliferationwhen seeded in 3 mm-transwell
inserts (median level of inhibition: 51%; 25th to 75th
percentile: 37% to 54%) but not when seeded in .4 mm-
transwell inserts (Figure 3A). Thus, the eosinophils were only
capable of exerting a negative inﬂuence on allogeneic T cell
proliferation under culture conditions that were permissive
for cell-to-cell contact.
Blocking EDN or ECP Does not Prevent Eosinophilic
Inhibition of Allogeneic T Cell Proliferation
To determine the eosinophilic proteins responsible for the
inhibitory effect of eosinophils on allogeneic T cell prolifer-
ation, antibodies directed against EDN and ECP were added
separately to the MLR/eosinophilhealthy and MLR/eosino-
philHSCT cocultures. Blocking either EDN (Figure 3B) or ECP
(Figure 3C) did not prevent the inhibitory effect of healthy
eosinophils. Rather, the inhibitory effect was signiﬁcantly
strengthened. The same tendency was observed for MLRcultures with eosinophils from HSC transplant recipients
(chronic GVHD, n ¼ 2; no GVHD, n ¼ 2), ie, blocking EDN
(Figure 3D) or ECP (Figure 3D) resulted in a further reduction
in allogeneic T cell proliferation, though the effect was not
signiﬁcant. Furthermore, we were unable to detect any
inhibitory effect of either native EDN (Figure 3B) or native
ECP (Figure 3C) on allogeneic T cell proliferation. Unexpect-
edly, the addition of IgG1 isotype control to MLR/eosino-
philhealthy andMLR/eosinophilHSCT cocultures tended to cause
an increase in allogeneic T cell proliferation, although this
effect of IgG1 was not signiﬁcant (Figure 3B, D).Impact of IL-10 and its Receptor on Eosinophilic
Inhibition of T Cell Expansion
To explore the possibility that eosinophilic production of
IL-10 contributes to the suppression of allogeneic T cell
proliferation by eosinophils, we added antibodies that
recognize secreted IL-10 or the IL-10 receptor CD210 to the
MLR/eosinophilhealthy cocultures. Treatment with either
antieIL-10 (Figure 3E) or anti-CD210 (Figure 3F) antibodies
did not result in the recovery of allogeneic Tcell proliferation,
and treatment with the combination of the 2 antibodies did
not restore T cell proliferation (n ¼ 4 peripheral blood
eosinophil donors; P ¼ .79; data not shown).No Inﬂuence of IDO Activity on the T Cell Inhibitory
Capacity of Eosinophils
We next determined the activity of IDO in the MLR/eosi-
nophilhealthy cocultures. The amounts of the IDO metabolite
kynurenine in the MLR/eosinophilhealthy coculture superna-
tants were below the level of quantitation, indicating that
Figure 3. Contributions of cell-to-cell contacts, EDN, ECP, IL-10, and CD210 to the inhibitory effect of eosinophils on allogeneic T cell proliferation. (A) MLR and MLR/
eosinophilhealthy cocultures were established in transwell culture systems that were either permissive or nonpermissive for cell-to-cell contacts (n ¼ 8 peripheral
blood eosinophil donors). Each data point represents the median counts per minute value of 3 to 4 replicate cultures derived from 1 individual. (B-F) Contribution of
EDN, ECP, IL-10, and CD210 to eosinophilic inhibition of allogeneic T cell proliferation was assessed by supplementing MLR/eosinophil cocultures with antibodies
against: EDN (B, D), ECP (C, D), IL-10 (E), and CD210 (F) or isotype controls (B, D, F). In selected experiments native EDN (B, n ¼ 3) or native ECP (C, n ¼ 3) was added to
MLR cultures. The ratio of eosinophils to PBMC in the cocultures was 1:1 (þ, A-F). (D) Eosinophils from HSC transplant recipients (HSCT) with chronic GVHD (black
circles) or no GVHD (grey triangles). Proliferation was assessed by 3H-thymidine incorporation. Each data point represents the median value of 3 to 6 replicate
cultures derived from 1 individual. Horizontal bars represent the groupmedians (A-F). Statistical analyses were performed using the pairedWilcoxon signed-rank test
(A-F) or the Mann-Whitney U-test (B-F). xRepeated data from Figure 1B. Number of blocked cocultures: EDN (B) n ¼ 9; ECP (C) n ¼ 9; IL-10 (E) n ¼ 7; CD210 (F) n ¼ 5.
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shown).
Galectin-10 Expression Is Increased in the Eosinophils of
HSC Transplant Recipients
To examine whether the inhibitory effect of eosinophils
on allogeneic T cell proliferation is due to increased expres-
sion of galectin-10, the mRNA levels of galectin-10 were
quantiﬁed in eosinophils obtained from HSC transplant
recipients and compared with the corresponding levels in
the eosinophils of healthy individuals. Patients who weresuffering from chronic GVHD as well as patients without
GVHD had signiﬁcantly higher levels of galectin-10 mRNA,
compared with healthy individuals (Figure 4A). However, we
were not able to neutralize the inhibitory effect of healthy
eosinophils on allogeneic T cell proliferation by adding
antiegalectin-10 antibodies to the cocultures (Figure 4B). In
MLR cultures with eosinophils from HSC transplant
recipients (chronic GVHD, n ¼ 2; no GVHD, n ¼ 2), the effect
tended to be the same, ie, blocking galectin-10 did not
dampen eosinophilic inhibition of allogeneic T cell prolifer-
ation (Figure 4C).
Figure 4. Expression levels of mRNA for galectin-10 and neutralization of the galectin-10 protein. (A) The levels of galectin-10 mRNA in eosinophils from HSC
transplant recipients and healthy controls were analyzed using real-time quantitative PCR. Shown are the transcript levels of galectin-10 relative to healthy controls,
as determined by the Pfafﬂ method. Hypoxanthine phosphoribosyltransferase 1 was used as an endogenous control. For all patient eosinophils, each data point
represents the mean of duplicate PCR reactions. For control eosinophils, each data point represents 1 PCR reaction, except in 3 instances where control samples were
run 2 times and the mean values are shown. (B, C) Antiegalectin-10 antibodies were added to MLR/eosinophilhealthy (B) and MLR/eosinophilHSCT cocultures (C). The
ratio of eosinophils to PBMC in the cocultures was 1:1 (þ; B, C). (C) Eosinophils from HSC transplant recipients (HSCT) with chronic GVHD (black circles) or no GVHD
(grey triangles). Proliferation was assessed by 3H-thymidine incorporation. Each data point represents the median value of 3 to 6 replicate cultures derived from 1
individual. Horizontal bars represent the group medians (A-C). Statistical analyses were performed using the Mann-Whitney U-test (A-C) or the paired Wilcoxon
signed-rank test (B, C). xRepeated data from Figure 1B. xxRepeated data from Figure 3D. (A) n ¼ 10 healthy controls; (B) Galectin-10 blocked cocultures n ¼ 13.
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The present study shows that eosinophils from both
healthy subjects and HSC transplant recipients with or
without chronic GVHD have the ability to decrease allogeneic
T cell proliferation in vitro. Neutrophils lack this T cell regu-
latory activity, as has been shown by others [22]. We further
show that the inhibitory capacity of healthy eosinophils is
both cell number-dependent and eosinophil-speciﬁc. Optimal
eosinophilic Tcell suppressionwas achievedwhen a ratio of 1
eosinophil per PBMC responder cellwas used,which is similar
to the ratio used to demonstrate the T cellesuppressive ca-
pacity of naturally occurring Tregs [23]. Although there was a
trend for eosinophils from transplant recipients to be either
less (chronic GVHD) or more (no GVHD) suppressive than
those of healthy individuals, this did not attain statistical
signiﬁcance. We might have been able to demonstrate a sig-
niﬁcant difference in suppressive capacity between healthy
eosinophils and eosinophils from transplant recipients had
more patients been available for inclusion in our study.
Mesenchymal stromal cells can suppress allogeneic T cell
activity and expand the Treg population inMLR cultures [24].
With this in mind, we investigated whether the inhibitory
effect of eosinophils on allogeneic T cell proliferation might
be due to an increase in the frequency of proliferating
Tregs. However, we found reduced frequencies of prolifer-
ating CD25þCD127low Tregs in our MLR/eosinophilhealthy co-
cultures. Thus, it appears that healthy eosinophils have adirect negative effect on T cell proliferation that is not driven
by an increase in the frequency of proliferating Tregs. Instead,
one can theorize that it is the eosinophil itself that is directly
responsible for the suppressed allogeneic T cell proliferation
that we observed in our MLR/eosinophilhealthy cocultures.
We attempted to identify eosinophilic T cellesuppressive
mechanisms using eosinophils isolated from both healthy
subjects and HSC transplant recipients. We demonstrate that
healthy eosinophils have the capacity to reduce the fre-
quency of proliferating CD4þ conventional T cells and CD8þ T
cells, a feature that eosinophils have in common with Tregs
[25]. It was also clear that inhibition of allogeneic T cell
proliferation by healthy eosinophils is dependent upon cell-
to-cell contact. The regulation of T cell proliferation through
cell-to-cell contact is another characteristic that eosinophils
share with naturally occurring Tregs [26]. The requirement
for cell-to-cell contact does not preclude the possibility that
soluble factors may be important mediators of eosinophilic
suppression, as close contact would increase the local con-
centrations of these putative mediators. In the 1980s,
Peterson et al. showed that the puriﬁed eosinophil granule
proteins ECP and EDN both have the capacity to reduce
lymphocyte proliferation [12]. However, the addition of an-
tibodies directed against ECP and EDN to either MLR/eosi-
nophilhealthy or MLR/eosinophilHSCT cocultures in our study
did not diminish the ability of the eosinophils to inhibit
allogeneic T cell proliferation. Our results rather suggest that
J. Andersson et al. / Biol Blood Marrow Transplant 20 (2014) 1891e1898 1897blocking ECP or EDN potentiates the capacity of eosinophils
to inhibit allogeneic T cell proliferation. In our system, ECP
and EDN are not the T cell inhibitory agents of eosinophils. It
could be argued that because we blocked ECP and EDN
separately, EDN might “take over” in the absence of ECP and
maintain eosinophilic suppression of allogeneic T cell pro-
liferation, and vice versa. However, the lack of suppressive
effect of both native EDN and native ECP on allogeneic T cell
proliferation contradicts this theory.
IL-10 is a cytokine implicated in the T cellesuppressive
function of mesenchymal stromal cells [24]. It has been
shown to alleviate GVHD in a human explant model of skin
GVHD [27]. Moreover, eosinophils are capable of producing
IL-10 [28]. Consequently, we hypothesized that the eosino-
phils might be affecting the levels of IL-10 in our in vitro
model of GVHD, resulting in repression of allogeneic T cell
proliferation. However, the introduction of antibodies
against secreted IL-10 and the IL-10 receptor did not prevent
the healthy eosinophils from dampening allogeneic T cell
proliferation. This would suggest that IL-10 is nonessential
for eosinophilic suppression of T cell proliferation. A recent
review indicates that IL-10 is not essential for the suppres-
sive function of naturally occurring Tregs, either [29].
IDO is another T cell suppressor [30] that is constitutively
expressed by human eosinophils and has been shown to
mediate eosinophilic suppression of type 1 T helper cell
proliferation [13]. Importantly, IDO-mediated tryptophan
degradation has been revealed to mediate the suppressive
function of mesenchymal stromal cells [31]. However, we
could not detect quantiﬁable levels of IDOmetabolites, which
implies that IDO was not present in sufﬁcient levels to play a
role. To conclude, ECP, EDN, IL-10, and IDOdonot appear to be
candidates for the role of eosinophilic T cell suppressor.
We next focused on galectin-10, which has been proposed
to be an important mediator of the immunosuppressive ac-
tivity of naturally occurring Tregs in humans [16]. The human
eosinophil is the leukocyte that contains the highest amount
of galectin-10, which accounts for roughly 10% of the cell’s
protein content [15]. We found that eosinophilic galectin-10
mRNA expressionwas increased in HSC transplant recipients
compared with that of healthy subjects. If galectin-10 is
indeed an immunoregulatory protein, the boosting of its
production in patients with a dysfunctional immune system,
eg, individuals who recently underwent transplantation,
would make sense. However, we were unable to demon-
strate that neutralizing galectin-10 has a signiﬁcant effect on
the inhibition of allogeneic T cell proliferation by either
healthy eosinophils or eosinophils from HSC transplant re-
cipients. This was perhaps to be expected, as Kubach et al.
also failed to abrogate the regulatory capacity of Tregs
through the administration of the same antiegalectin-10
antibodies [16]. It is not known how galectin-10 is excreted
from eosinophils or Tregs or how this molecule exerts its
putative suppressive function. It is possible that very close
cell-to-cell contact is required, which might hinder the
access of antiegalectin-10 antibodies, and consequently,
prevent the neutralization of galectin-10edependent sup-
pression of allogeneic T cell proliferation in our cocultures. It
is of course also possible that eosinophilic galectin-10 has a
completely different function that is not related to the
regulation of allogeneic T cell proliferation. Future studies
will focus on analyzing the impact of silenced galectin-10
expression on eosinophil function. This endeavor may
prove difﬁcult, as eosinophils are not as amenable to trans-
fection as are lymphocytes.In terms of clinical applicability, our study has some
limitations. First, all conclusions concerning the mechanisms
underlying the inhibition of allogeneic T cell proliferation by
eosinophils, ie, the requirement for cell-to-cell contact, the
inhibition of different T cell subtypes, and the exclusion of
ECP, EDN, IL-10, IDO, and galectin-10 as eosinophilic in-
hibitors are mainly based on experiments using healthy eo-
sinophils. Eosinophils from only 4 HSC transplant recipients
were analyzed in blocking experiments with a-ECP, a-EDN,
and aegalectin-10 antibodies. Hence, statements concerning
the inhibitory mechanisms of eosinophils from HSC trans-
plant recipients would be highly speculative. Second, we
only included HSC transplant recipients without systemic
glucocorticoid treatment in our study. This choice was based
on the fact that systemic corticosteroids promote eosino-
philic apoptosis [32] and cause a general downregulation of
cell surface markers on peripheral blood eosinophils in pa-
tients with GVHD [33]. By only including untreated patients,
we eliminated HSC transplant recipients who suffered from
more severe GVHD, making extrapolation of our ﬁndings to
eosinophils from extensive chronic GVHD patients trouble-
some. On the other hand, by so doing we prevented the
introduction of a confounder previously reported by Mor-
tensen et al.; that is, ongoing glucocorticoid treatment [10].
Third, the majority of patients included in our study received
reduced-intensity conditioning therapy and peripheral blood
stem cells from unrelated donors. Hence, eosinophils from
HSC transplant recipients who have undergone myeloa-
blative conditioning and received bone marrow stem cells
from related donors might behave differently in our in vitro
model of GVHD.
Finally, we could not see any difference regarding the
suppressive capacity of eosinophils from patients with or
without ongoing chronic GVHD. However, this result was
obtained using healthy PBMC as responder cells. Had we
instead preparedMLR/eosinophil cocultures using responder
cells from transplant recipients with or without chronic
GVHD, the outcome might have been different. Further,
coculturing responder cells and eosinophils donated by the
same transplant recipient would have been a more accurate
representation of the in vivo situation, in addition to
increasing the clinical applicability of our in vitro data. In
future studies, the potential capacity of eosinophils to
moderate the severity of GVHD will be monitored prospec-
tively by studying how eosinophil counts and eosinophilic
suppressive capacity correlate with the occurrence and the
severity of GVHD. If such a correlation is conﬁrmed, it might
open up a new type of transfusion therapy based on eosin-
ophils from healthy blood donors for the prevention or
treatment of chronic GVHD.
ACKNOWLEDGMENTS
Financial disclosure statement: This work was supported
by the Cancer and Allergy Foundation (#149781), ALF-
Göteborg (#71580), Strategic ALF-Transplantation (#74080),
the Västra Götaland Region (VGFOUREG-155731), Göteborg
Medical Society (GLS-102901), Sahlgrenska University
Foundation (#90020), the IngaBritt and Arne Lundberg
Foundation, Wilhelm and Martina Lundgren’s Science Fund
(vet1152-155/2011), and the Assar Gabrielsson Foundation
(FB 10-48).
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Authorship statement: J.A. and J.C. contributed equally to
this study and should both be considered ﬁrst authors.
J. Andersson et al. / Biol Blood Marrow Transplant 20 (2014) 1891e18981898REFERENCES
1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease
biology and therapy. Nat Rev Immunol. 2012;12:443-458.
2. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote
immune reconstitution in HLA-haploidentical transplantation. Blood.
2011;117:3921-3928.
3. Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review: hitting the
right spot with mesenchymal stromal cells. Stem Cells. 2010;28:
1446-1455.
4. Aisa Y, Mori T, Nakazato T, et al. Blood eosinophilia as a marker of
favorable outcome after allogeneic stem cell transplantation. Transpl
Int. 2007;20:761-770.
5. Kim DH, Popradi G, Xu W, et al. Peripheral blood eosinophilia has a
favorable prognostic impact on transplant outcomes after allogeneic
peripheral blood stem cell transplantation. Biol Blood Marrow Trans-
plant. 2009;15:471-482.
6. Sato T, Kobayashi R, Nakajima M, et al. Signiﬁcance of eosinophilia after
stem cell transplantation as a possible prognostic marker for favorable
outcome. Bone Marrow Transplant. 2005;36:985-991.
7. Imahashi N, Miyamura K, Seto A, et al. Eosinophilia predicts better
overall survival after acute graft-versus-host-disease. Bone Marrow
Transplant. 2010;45:371-377.
8. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host
disease after allogeneic blood stem cell transplantation. Blood. 2001;
98:1695-1700.
9. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic
graft-versus-host disease: National Institutes of Health consensus
development project on criteria for clinical trials in chronic graft-
versus-host disease: III. Biomarker Working Group Report. Biol Blood
Marrow Transplant. 2006;12:126-137.
10. Mortensen KB, Gerds TA, Bjerrum OW, et al. The prevalence and
prognostic value of concomitant eosinophilia in chronic graft-versus-
host disease after allogeneic stem cell transplantation. Leuk Res.
2014;38:334-339.
11. Akuthota P, Wang HB, Spencer LA, Weller PF. Immunoregulatory roles
of eosinophils: a new look at a familiar cell. Clin Exp Allergy. 2008;38:
1254-1263.
12. Peterson CG, Skoog V, Venge P. Human eosinophil cationic proteins
(ECP and EPX) and their suppressive effects on lymphocyte prolifera-
tion. Immunobiology. 1986;171:1-13.
13. Odemuyiwa SO, Ghahary A, Li Y, et al. Cutting edge: human eosinophils
regulate T cell subset selection through indoleamine 2,3-dioxygenase.
J Immunol. 2004;173:5909-5913.
14. Ackerman SJ, Loegering DA, Gleich GJ. The human eosinophil Charcot-
Leyden crystal protein: biochemical characteristics and measurement
by radioimmunoassay. J Immunol. 1980;125:2118-2126.
15. Weller PF, Bach DS, Austen KF. Biochemical characterization of human
eosinophil Charcot-Leyden crystal protein (lysophospholipase). J Biol
Chem. 1984;259:15100-15105.
16. Kubach J, Lutter P, Bopp T, et al. Human CD4þCD25þ regulatory T
cells: proteome analysis identiﬁes galectin-10 as a novel marker
essential for their anergy and suppressive function. Blood. 2007;110:
1550-1558.17. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host
syndrome in man. A long-term clinicopathologic study of 20 Seattle
patients. Am J Med. 1980;69:204-217.
18. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease: I. Diagnosis and staging working group
report. Biol Blood Marrow Transplant. 2005;11:945-956.
19. Ingelsten M, Gustafsson K, Oltean M, et al. Is indoleamine 2,3-
dioxygenase important for graft acceptance in highly sensitized
patients after combined auxiliary liver-kidney transplantation? Trans-
plantation. 2009;88:911-919.
20. Pfafﬂ MW. A new mathematical model for relative quantiﬁcation in
real-time RT-PCR. Nucleic Acids Res. 2001;29:2002-2007.
21. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell
proliferation-associated human nuclear antigen deﬁned by the
monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
22. Rieber N, Wecker I, Neri D, et al. Extracorporeal photopheresis in-
creases neutrophilic myeloid-derived suppressor cells in patients with
GvHD. Bone Marrow Transplant. 2014;49:545-552.
23. Baecher-Allan C, Brown JA, Freeman GJ, Haﬂer DA. CD4þCD25 high reg-
ulatory cells in humanperipheral blood. J Immunol. 2001;167:1245-1253.
24. Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by
human mesenchymal stem cells is required to suppress T lymphocyte
and natural killer function and to induce CD4þCD25highFOXP3þ regu-
latory T cells. Stem Cells. 2008;26:212-222.
25. Dieckmann D, Plottner H, Dotterweich S, Schuler G. Activated CD4þ
CD25þ T cells suppress antigen-speciﬁc CD4þ and CD8þ T cells but
induce a suppressive phenotype only in CD4þ T cells. Immunology.
2005;115:305-314.
26. Hagness M, Henjum K, Landskron J, et al. Kinetics and activation re-
quirements of contact-dependent immune suppression by human
regulatory T cells. J Immunol. 2012;188:5459-5466.
27. Wang XN, Lange C, Schulz U, et al. Interleukin-10 modulation of
alloreactivity and graft-versus-host reactions. Transplantation. 2002;
74:772-778.
28. Lamkhioued B, Gounni AS, Aldebert D, et al. Synthesis of type 1 (IFN
gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosin-
ophils. Ann N Y Acad Sci. 1996;796:203-208.
29. Schmetterer KG, Neunkirchner A, Pickl WF. Naturally occurring regu-
latory T cells: markers, mechanisms, and manipulation. FASEB J. 2012;
26:2253-2276.
30. Forouzandeh F, Jalili RB, Germain M, et al. Differential immunosup-
pressive effect of indoleamine 2,3-dioxygenase (IDO) on primary hu-
man CD4þ and CD8þ T cells. Mol Cell Biochem. 2008;309:1-7.
31. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells
inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-
mediated tryptophan degradation. Blood. 2004;103:4619-4621.
32. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of gluco-
corticoids on the rate of apoptosis in neutrophilic and eosinophilic
granulocytes. J Immunol. 1996;156:4422-4428.
33. Cromvik J, Johnsson M, Vaht K, et al. Eosinophils in the blood of he-
matopoietic stem cell transplanted patients are activated and have
different molecular marker proﬁles in acute and chronic graft-versus-
host disease. Immun Inﬂamm Dis. 2014;2:99-113.
